Boxer Capital Management has bolstered its investment in Kodiak Sciences (KOD), acquiring an additional 225,000 shares worth approximately $5.81 million in the first quarter, as revealed in a May 15 SEC filing. This increase brings Boxer’s total stake to 1,361,000 shares, valued at $51.88 million, representing 6.81% of its reportable assets under management (AUM). Kodiak Sciences has seen a remarkable 1,000% surge in share price over the past year, significantly outpacing the S&P 500’s 25% gain.
This strategic move by Boxer Capital suggests confidence in Kodiak’s potential as it approaches critical clinical milestones, particularly with positive Phase 3 data for its lead candidate, KSI-301, and upcoming trial results for wet age-related macular degeneration. Despite a quarterly net loss of $58.2 million and no revenue, Kodiak’s strong cash position of $169.5 million should sustain operations through 2027.
For investors, this transaction underscores a high-risk, high-reward scenario in the biotech sector, where upcoming trial outcomes could either propel Kodiak into commercial success or lead to further setbacks.
Source: fool.com